ClinicalTrials.gg
RecruitingNCT07629024Updated Nov 18, 2026

Rehabilitation Assessment of Motor Function In Cerebral Palsy Using Explainable AI

An observational study in Cerebral Palsy Children, sponsored by Riphah International University. Recruiting at 4 sites in Pakistan. Open to participants aged 4 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Riphah International University · Observational

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 18, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
4 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 135 studies in Cerebral Palsy by Riphah International University — 37 open to participants now, 37 under way, none of them phase 3. Cerebral Palsy · Riphah International University.

Planned enrollment
2nd of 10
200 · median 108
Started
2026
with 17 others
Observational
10 of 135
3 open now
Primary completion
2027-03
later than 29 of 36 live
Registered
123rd of 135
by date

Among the 135 studies in Cerebral Palsy by Riphah International University, this one is the 2nd largest by planned enrollment of the 10 observational ones that give a count, is one of 18 that started in 2026, is one of 10 observational ones, reaches primary completion later than 29 of the 36 other live ones, and was the 123rd registered.

Cerebral Palsy

1,942 studies on the registry are indexed under Cerebral Palsy; 456 are open to participants now.

Browse Cerebral Palsy studies →

Open to participants now

37 of the 135 studies in Cerebral Palsy by Riphah International University are open now, in 1 country. Recruiting first, the newest first:

31 more — sign in →

By country, each count listing its studies:

All 37 open studies →

Where they have run

Who these studies take

Of the 271 Cerebral Palsy studies recruiting now, 26 (10%) set no upper age limit and 237 (87%) stop at 75 or younger; 256 take children under 18; 53 take healthy volunteers.

This study: 4 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 135 studies in Cerebral Palsy by Riphah International University, or all of them as a file.
02

Study summary

The goal of this observational study is to develop and validate an AI-based prediction model for functional mobility and gait outcomes in children with cerebral palsy using low-cost clinical and gait data collected in rehabilitation settings in Pakistan.

Read the detailed description

Children with cerebral palsy (CP) commonly experience limitations in functional independence and mobility, which significantly affect participation and quality of life. Accurate assessment of these functional abilities is essential for rehabilitation planning, prognosis estimation, and monitoring treatment outcomes. However, conventional assessment methods largely depend on therapist observation and standardized clinical scales, which may be subjective, time-consuming, and less sensitive to complex interactions among clinical variables.

03

Conditions studied

  • Cerebral Palsy Children

Browse trials for

Keywords

  • CP Assesment
  • Explainable machine learning
  • Gait symmetry
  • Functional independence
04

Who can participate

Ages eligible
4 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Children with cerebral palsy classified within Gross Motor Function Classification System (GMFCS) Levels I-III who are ambulatory with or without assistive devices and receiving routine physiotherapy rehabilitation. Participants from all cerebral palsy subtypes will be included for clinical, functional, and gait assessment related to AI-based evaluation of functional mobility and gait outcomes.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 4 to18 years
  • Diagnosed any motor type of cerebral palsy (spastic, dyskinetic, ataxic, mixed),)
  • GMFCS levels I -III (able to walk with or without an assistive device).
  • All participants must be able to ambulate at least 10 meters with or without an assistive device.
  • Capable of following simple verbal instructions.
  • Parental and child assent

Exclusion criteria

Exclusion Criteria:

  • Recent orthopedic or neurosurgical interventions (\<6 months).
  • Uncontrolled seizures affecting gait.
  • Non-ambulatory (GMFCS IV-V) or cognitive impairments preventing cooperation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Ambulatory Children with Spastic Cerebral Palsy (GMFCS I-III)

    Children diagnosed with spastic cerebral palsy who are ambulatory and classified within Gross Motor Function Classification System (GMFCS) Levels I to III. Participants will undergo clinical, functional, and gait assessments for AI-based prediction of functional mobility and gait outcomes

    Other: AI-Based Functional Mobility and Gait Assessment

Interventions

  • OtherAI-Based Functional Mobility and Gait Assessment

    Participants will continue receiving their standard/routine physiotherapy rehabilitation program as prescribed by their treating therapist. The study will involve observational collection of clinical, functional, and gait-related data using standardized assessment tools, and AI-based video analysis. No additional therapeutic intervention will be administered specifically for research purposes.

06

What researchers measure

Primary outcomes

  1. GMFM-88

    GMFM (Gross Motor Function Measure) Reliability: Excellent. Internal consistency Cronbach's α \~0.997-1.00; intra- and inter-rater ICC \~0.994-0.999 (both GMFM-88 \& GMFM-66) Validity: Construct and concurrent validity supported by strong correlations with related motor function classifications (e.g., GMFCS, PEDI mobility)

    Time frame: Baseline to 6 months followup

  2. Markerless Gait Analysis

    Gait videos will be processed using a validated markerless pose estimation framework . Spatiotemporal and kinematic gait parameters will be extracted, including but not limited to: * Step length symmetry * Cadence * Stride time variability * Joint angle trajectories * Temporal asymmetry indices

    Time frame: Baseline to 6 months

  3. Edinburgh visual gait scale (EVGS)

    Edinburgh visual gait scale (EVGS) EVGS can be a supportive tool that adds quantitative data instead of only qualitative assessment to a video only gait evaluation. Interobserver agreement is 60-90% and Kappa values are 0.18-0.85 for the 17 items in EVGS. Reliability is higher for distal segments (foot/ankle/knee 63-90%; trunk/pelvis/hip 60-76%). Agreement between EVGS and 3DGA is 52-73%.

    Time frame: Baseline to 6 Months

  4. WeeFIM (Functional Independence Measure for Children)

    WeeFIM (Functional Independence Measure for Children) Reliability: High internal consistency and ICCs (motor and cognitive scales) \~0.91-0.98 in children with cerebral palsy Validity: Construct and external validity supported (scale fits Rasch model expectations and correlates with related developmental measures)

    Time frame: Baseline to 6 months

Secondary outcomes

  1. Feasibility of markerless video-based gait analysis for routine physiotherapy assessment in low-resource clinical settings

    Feasibility will be evaluated using: (1) video acquisition success rate; (2) data processing completion rate; (3) time required for analysis; and (4) clinician usability and interpretability feedback, obtained through structured questionnaires and semi-structured interviews with practicing physiotherapists regarding SHAP-based model outputs.

    Time frame: Through study completion, 12 month

  2. Predictive accuracy of the machine learning model for gait and motor function

    Model performance will be evaluated using RMSE, MAE, and R² for continuous outcomes. Explainability will be assessed using SHAP values, with examination of feature importance consistency across cross-validation folds. based on gait and motor function data collected from participants with ambulatory cerebral palsy.

    Time frame: At model validation ,post data collection ,6 month

  3. Robustness of model predictive performance and change in functional and gait outcomes across heterogeneous therapy exposure contexts

    The Phase 2 trained model will be applied to 6-month follow-up data without retraining. Predictive performance (RMSE, MAE, R²) will be compared across therapy exposure subgroups (regular vs. irregular/no physiotherapy). Temporal prognosis will additionally be characterized using change from baseline in GMFM-66, WeeFIM, and EVGS, alongside gait symmetry indices derived from video analysis.

    Time frame: Baseline to 6-month follow-up

07

Study locations

2 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Mar 2027, 5 months after the start.

Of 217 non-industry observational studies under Cerebral Palsy, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 60. This study's planned 5 months is below that.

Counting every sponsor, half of 221 studies reached it within 21 months; a quarter within 8 and three quarters within 60.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: start Aug 2026 → Oct 2026 and primary completion Jun 2027 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2026
First posted
Jun 5, 2026
StartActual
Oct 19, 2026was Aug 2026
Primary completionEst.
Mar 30, 2027was Jun 2027
CompletionEst.
Dec 30, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 18, 2026
Sites
4 sites changed recruiting status (2 now recruiting, 1 now active, not recruiting, …)
Show 4 sites
  • Alfarabi special education center · Islamabad, Pakistanno status→Recruiting
  • Army special education Academy · Islamabad, Pakistanno status→Active, not recruiting
  • National institute of Rehabilitation medicine · Islamabad, Pakistanno status→Recruiting
  • Karachi institue of neurological diseases and rehabilitation(KIND-R) · Karachi, Pakistanno status→Not yet recruiting
Nov 18, 2026
Start date
Aug 30, 2026→Oct 19, 2026 (actual)
Nov 18, 2026
Primary completion
Jun 30, 2027→Mar 30, 2027
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Not yet recruiting→Recruiting
    4 sites changed recruiting status (2 now recruiting, 1 now active, not recruiting, …)
    Show 4 sites
    • Alfarabi special education center · Islamabad, Pakistanno status→Recruiting
    • Army special education Academy · Islamabad, Pakistanno status→Active, not recruiting
    • National institute of Rehabilitation medicine · Islamabad, Pakistanno status→Recruiting
    • Karachi institue of neurological diseases and rehabilitation(KIND-R) · Karachi, Pakistanno status→Not yet recruiting
    Start date Aug 30, 2026→Oct 19, 2026 (now actual)
    Primary completion Jun 30, 2027→Mar 30, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07629024
Responsible party
Sponsor
First posted
Jun 5, 2026
Start date
Oct 19, 2026
Primary completion
Mar 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Qamar Mehmood, Phd Rehab
Contact
qamar.mehmood@riphah.edu.pk
03335151063
Sidra Ghias, PhD* Rehab
principal investigator · Riphah International university Isalambad

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion